These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 17332651)

  • 1. Elevation of tumour marker CA-125 in serum & body fluids: interpret with caution.
    Hussain SF; Camilleri P
    Indian J Med Res; 2007 Jan; 125(1):10-2. PubMed ID: 17332651
    [No Abstract]   [Full Text] [Related]  

  • 2. CA-125: a biomarker put to the test.
    Schmidt C
    J Natl Cancer Inst; 2011 Sep; 103(17):1290-1. PubMed ID: 21852262
    [No Abstract]   [Full Text] [Related]  

  • 3. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
    Petignat P; Vajda D; Obrist R
    Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interest of CA 125 level in management of ovarian cancer].
    Coussy F; Chéreau E; Daraï E; Dhombres F; Lotz JP; Rouzier R; Selle F
    Gynecol Obstet Fertil; 2011 May; 39(5):296-301. PubMed ID: 21515085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumour markers in ovarian tumours.
    von Schlippe M; Rustin GJ
    Forum (Genova); 2000; 10(4):383-92. PubMed ID: 11535987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CA-125 monitoring in ovarian cancer: patient survey responses to the results of the MRC/EORTC CA-125 Surveillance Trial.
    Markman M; Petersen J; Belland A; Burg K
    Oncology; 2010; 78(1):1-2. PubMed ID: 20215782
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: "clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation".
    Menczer J
    Gynecol Oncol; 2005 Mar; 96(3):906-7; author reply 907. PubMed ID: 15721450
    [No Abstract]   [Full Text] [Related]  

  • 8. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
    Markman M; Federico M; Liu PY; Hannigan E; Alberts D
    Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids.
    Sevinc A; Buyukberber S; Sari R; Kiroglu Y; Turk HM; Ates M
    Gynecol Oncol; 2000 May; 77(2):254-7. PubMed ID: 10785474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
    Topalak O; Saygili U; Soyturk M; Karaca N; Batur Y; Uslu T; Erten O
    Gynecol Oncol; 2002 Apr; 85(1):108-13. PubMed ID: 11925128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CA 125 kinetic pattern during chemotherapy].
    Carcenac G; Georges A; Bordenave L
    Ann Biol Clin (Paris); 2004; 62(1):99-102. PubMed ID: 15047499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer antigen 125 and prognosis.
    Høgdall E
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):4-8. PubMed ID: 18196998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.
    Tuxen MK; Sölétormos G; Dombernowsky P
    Br J Cancer; 2001 May; 84(10):1301-7. PubMed ID: 11355938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening.
    Whitehouse C; Solomon E
    Gynecol Oncol; 2003 Jan; 88(1 Pt 2):S152-7. PubMed ID: 12586109
    [No Abstract]   [Full Text] [Related]  

  • 15. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
    Oehler MK; Sütterlin M; Caffier H
    Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter commenting on the article "CA 125 expression pattern, prognosis and correlation with serum CA 125 in ovarian tumor patients" (104:508-515) by Hogdall, et al and on the Editorial "CA 125: megadaltons of novel opportunities" (104:505-507).
    van Altena AM; de Hullu JA; Massuger LF
    Gynecol Oncol; 2007 Nov; 107(2):355-6. PubMed ID: 17707896
    [No Abstract]   [Full Text] [Related]  

  • 17. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
    Gadducci A; Cosio S; Fanucchi A; Negri S; Cristofani R; Genazzani AR
    Gynecol Oncol; 2004 Apr; 93(1):131-6. PubMed ID: 15047226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Contribution of dynamic interpretation of CA 125 measurements to the understanding of an atypical clinical case].
    Riedinger JM; Mousseau M; Gauchez AS
    Ann Biol Clin (Paris); 2008; 66(3):333-40. PubMed ID: 18558573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis.
    Sørensen SS; Mosgaard BJ
    Dan Med Bull; 2011 Nov; 58(11):A4331. PubMed ID: 22047929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CA-125 screening for ovarian cancer in patients with dermatomyositis.
    Whitmore SE; Anhalt GJ; Provost TT; Zacur HA; Hamper UM; Helzlsouer KJ; Rosenshein NB
    Gynecol Oncol; 1997 May; 65(2):241-4. PubMed ID: 9159332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.